Quantcast
Last updated on April 23, 2014 at 21:24 EDT

FDA Approves Expanded Indications of Merck’s Gardasil Vaccine

September 15, 2008

The FDA has approved Merck & Co’s Gardasil vaccine for the prevention of vaginal and vulvar cancer caused by human papillomavirus types 16 and 18 in girls and women ages nine to 26.

Regarding the prevention of vulvar and vaginal cancer, Gardasil’s manufacturer, Merck & Co followed more than 15,000 participants from the original studies for about two additional years. Approximately half had received Gardasil as part of the original study – the other half did not receive Gardasil and served as a control group.

Among females who tested negative for human papillomavirus (HPV) types 16 or 18 at the start of the study, Gardasil was highly effective in preventing these types of HPV-related precancerous vulvar and vaginal lesions, which are considered to be the precursors for cancer.

In the control group that did not receive the vaccine, 10 individuals developed precancerous vulvar lesions and nine developed precancerous vaginal lesions, all related to HPV types 16 or 18. No one in the Gardasil group developed either kind of precancerous lesion due to HPV types 16 or 18.

There was no evidence for benefit among women found to have been previously infected, prior to immunization, with the HPV types included in the vaccine. Therefore, to receive Gardasil’s full potential for benefit, it is important to be vaccinated prior to becoming infected with the HPV strains contained in the vaccine.

The FDA originally approved Gardasil in 2006 for girls and women ages nine to 26 for the prevention of cervical cancer caused by HPV types 16 and 18, precancerous genital lesions caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.

As part of the original approval, Merck committed to a safety surveillance study of 44,000 individuals in a managed care organization. The study is assessing short- and long-term safety for all of Gardasil’s approved uses.

Jesse Goodman, director of the FDA’s Center for Biologics Evaluation and Research, said: “There is now strong evidence showing that this vaccine can help prevent vulvar and vaginal cancers due to the same viruses for which it also helps protect against cervical cancer. While vulvar and vaginal cancers are rare, the opportunity to help prevent them is potentially an important additional benefit from immunization against HPV.”